Clinical studies done

  • Human cross over study has been conducted, and found that the Cureit formulation is ~ 10 times more bio available than the control.
  • A randomized, open label, balanced, three group, three treatments, parallel group comparative study to assess single-dose oral bioavailability of Cureit capsule (500 mg) with Curcumin with turmeric oil (500 mg) and Curcumin with Phospholipids (500 mg) capsule in healthy human adult male volunteers under fasting conditions
  • Dosage – 500mg/day
  • Patent status: Applied for patent (application no – 3646/CHE/2013)
  • Unique Product and Process international Patent pending
  • Unique Patent pending PNS Technology (Polar Non-Polar Sandwich technology) to ensure better Bio-availability and Bio-efficiency, Patent application number – E-1/11319/2015-CHE

Latest Comparative Human clinical study

Cureit is 6 times superior than Curcumin with Turmeric Oil & 5 times Superior than Curcumin with Phospholipids.

Cell line studies

  1. Cell culture study on the effect of Curcumin on Hyaluronidase inhibition – anti aging effects
  2. Cell culture study on the effect of Curcumin on Angiogenesis – wound healing effects
  3. Cell culture study on the effect of Curcumin on Boosting Phagocyte mediated immunity
  4. Cell culture study on the effect of Curcumin on Elastase inhibition – anti aging & anti inflammatory effects
  5. Cell culture study on the Cytotoxic effect of Curcumin anti cancer effects
  6. Cell culture study on the Antioxidant potential of Curcumin